Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 4/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13920696 | 0.79 | HDAC4 (0.36) | HDAC4COMTLATS1CYP17A1ALDH1A1 | |
| SCHEMBL15465534 | 0.70 | COMT (0.41) | HDAC4COMTALDH1A1MAPTCYP1A2 | |
| SCHEMBL27217329 | 0.67 | TRPV3 (0.35) | TRPV3 | |
| SCHEMBL28671291 | 0.67 | TRPV3 (0.35) | TRPV3 | |
| SCHEMBL15950989 | 0.66 | COMT (0.60) | COMTLATS1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL30231043 | 0.66 | COMT (0.35) | COMT | |
| SCHEMBL24260966 | 0.65 | COMT (0.42) | HDAC4COMTALDH1A1MAPTCYP1A2 | |
| SCHEMBL30287558 | 0.64 | HDAC4 (0.33) | HDAC4COMTUSP30 | |
| SCHEMBL34470028 | 0.64 | BRD4 (0.34) | TBK1 | |
| SCHEMBL15465213 | 0.64 | HDAC4 (0.36) | HDAC4COMTUSP30LATS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2974730-B1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO CO LTD (JP) | 2018-01-31 | — | — | EP | disclosed |
| EP-3144300-B1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | DAIICHI SANKYO CO LTD (JP) | 2017-12-20 | — | — | EP | disclosed |
| US-9845313-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-12-19 | — | — | US | disclosed |
| EP-3144300-A1 | METHODS OF PRODUCING 4-CYCLOALKYLOXYBENZENESULFONAMIDES | Daiichi Sankyo Company, Limited (JP) | 2017-03-22 | — | — | EP | disclosed |
| US-9597330-B2 | Drugs for treating respiratory diseases | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-03-21 | — | — | US | disclosed |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-01-05 | — | — | US | disclosed |
| US-9493448-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-15 | — | — | US | disclosed |
| EP-2813491-B1 | CYCLOALKANE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-02 | — | — | EP | disclosed |
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-02-11 | — | — | US | disclosed |
| EP-2974730-A1 | DRUG FOR RESPIRATORY DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-20 | — | — | EP | disclosed |
| EP-2813491-A1 | CYCLOALKANE DERIVATIVE | Daiichi Sankyo Co., Ltd. (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8889741-B2 | Cycloalkane derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-18 | — | — | US | disclosed |
| US-20140045862-A1 | Cycloalkane Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038486-A1 | DRUG FOR RESPIRATORY DISEASES | SCN1B, NHERF1, SCNN1A | HDAC4 1862/4885COMT 3656/4885TRPV3 108/4885 |
| US-20170001984-A1 | CYCLOALKANE DERIVATIVES | TRPV1, TRPA1, SCNN1A | HDAC4 2808/4885COMT 4364/4885TRPV3 10/4885 |
| US-20140045862-A1 | Cycloalkane Derivatives | TRPV1, TRPA1, SCNN1A | HDAC4 2808/4885COMT 4364/4885TRPV3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.